Krishna Mohan Vadrevu

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand et al. · The Lancet Infectious Diseases · 2021 · 433 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +6

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella, Siddharth Reddy, Harsh Jogdand et al. · The Lancet Infectious Diseases · 2021 · 360 citations · Full text

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Raches Ella, Siddarth Reddy, William C. Blackwelder et al. · The Lancet · 2021 · 358 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2

Gajanan Sapkal, Pragya D. Yadav, Raches Ella et al. · Journal of Travel Medicine · 2021 · 128 citations · Full text

Vaccination, B.1.1.7 Variant, Vaccine Development +7

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation

Brunda Ganneru, Harsh Jogdand, Vijaya Kumar Daram et al. · iScience · 2021 · 92 citations · Full text